PALANDRI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 800
EU - Europa 390
AS - Asia 146
AF - Africa 9
SA - Sud America 8
OC - Oceania 7
Totale 1.360
Nazione #
US - Stati Uniti d'America 798
RU - Federazione Russa 209
IE - Irlanda 49
HK - Hong Kong 48
SE - Svezia 47
SG - Singapore 37
IT - Italia 35
CN - Cina 33
DE - Germania 14
FI - Finlandia 10
CH - Svizzera 9
ID - Indonesia 8
AU - Australia 7
CI - Costa d'Avorio 7
IN - India 7
JO - Giordania 7
BR - Brasile 6
GB - Regno Unito 5
TR - Turchia 5
UA - Ucraina 5
PL - Polonia 2
AR - Argentina 1
AT - Austria 1
BD - Bangladesh 1
BY - Bielorussia 1
CA - Canada 1
DK - Danimarca 1
MA - Marocco 1
MX - Messico 1
NL - Olanda 1
RO - Romania 1
SC - Seychelles 1
VE - Venezuela 1
Totale 1.360
Città #
Santa Clara 449
Chandler 63
Dublin 49
Ashburn 43
Hong Kong 35
Singapore 29
Altamura 18
Lawrence 18
Moscow 15
Fairfield 12
Princeton 11
Beijing 10
Seattle 10
Shanghai 10
Bern 9
Jacksonville 9
Boston 8
Cambridge 8
Jakarta 8
Woodbridge 8
Abidjan 7
Boardman 7
Melbourne 7
San Diego 7
Washington 7
Wilmington 7
Buffalo 6
Medford 6
Mumbai 6
Helsinki 5
Houston 5
Andover 4
Izmir 4
Bremen 3
Brugherio 3
Falkenstein 3
Kent 2
Lappeenranta 2
London 2
Norwalk 2
Pistoia 2
Rome 2
Shenzhen 2
Warsaw 2
Ann Arbor 1
Arnsberg 1
Açu 1
Belo Horizonte 1
Curitiba 1
Falls Church 1
Foshan 1
Genoa 1
Guangzhou 1
Hillsboro 1
Hvidovre 1
Jinan 1
Köseköy 1
La Villa del Rosario 1
Minsk 1
Müllheim 1
New Bedfont 1
Ottawa 1
Pedro Luro 1
Rabat 1
Salvador 1
San Mateo 1
Taubaté 1
Turvo 1
Vienna 1
West Jordan 1
Yubileyny 1
Totale 952
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 121
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 99
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 96
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 94
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 92
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 89
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 88
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 84
Long-term follow-up of recovered MPN patients with COVID-19 82
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 79
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 77
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 66
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 63
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 61
Incidence of blast phase in myelofibrosis according to anemia severity 60
Breakthrough infections in MPN-COVID vaccinated patients 55
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 47
null 15
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial 11
Totale 1.379
Categoria #
all - tutte 4.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.878


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202029 0 0 0 0 0 0 0 8 5 7 6 3
2020/202136 1 2 4 2 0 5 0 10 2 5 2 3
2021/202254 3 1 3 1 0 0 0 15 1 0 9 21
2022/2023251 18 56 15 17 17 37 26 17 29 5 3 11
2023/2024160 5 11 21 16 15 27 5 37 1 10 3 9
2024/2025817 16 67 51 118 345 188 19 13 0 0 0 0
Totale 1.379